Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes.

摘要: Dipeptidyl peptidase 4 (DPP-4) inhibitors are a new class of drugs introduced in 2006 for treatment type 2 diabetes. In clinical trials lasting up to years, these agents well tolerated. Incidence hypoglycemia associated with the use DPP-4 is similar placebo, but markedly increased when used conjunction sulfonylureas (SUs). have neutral effect on body weight their combination thiazolidinedione (TZD) results slight gain averaging 0.5 1.3 kg compared placebo. Other adverse effects recorded more commonly versus placebo mild, and include nasopharyngitis, headache, possibly urinary tract infections (UTIs). postmarketing period, reported such as angioedema, rates infection, skin toxicity. Pancreatitis inconsistently relationship sitagliptin, one analysis links this agent elevated risk pancreatic cancer. also rare observed linagliptin studies. There no evidence that increase cardiovascular events or death. Overall, although short-term safety reassuring, needs be established by long-term close surveillance during period.